UBS Group Cuts Kenvue (NYSE:KVUE) Price Target to $21.00

Kenvue (NYSE:KVUE) had its price objective decreased by UBS Group from $23.00 to $21.00 in a research report sent to investors on Friday morning,Benzinga reports. UBS Group currently has a neutral rating on the stock.

Several other research analysts have also recently issued reports on KVUE. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $24.00 target price on shares of Kenvue in a report on Monday, February 3rd. Barclays decreased their price objective on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a report on Friday, January 17th. Citigroup cut their target price on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 15th. JPMorgan Chase & Co. boosted their price target on Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Finally, Deutsche Bank Aktiengesellschaft cut Kenvue from a “buy” rating to a “hold” rating and dropped their price objective for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. One analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $23.00.

Kenvue Stock Performance

Kenvue stock opened at $20.23 on Friday. Kenvue has a twelve month low of $17.67 and a twelve month high of $24.46. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $38.79 billion, a P/E ratio of 38.17, a PEG ratio of 2.16 and a beta of 1.45. The stock’s 50 day moving average is $21.54 and its 200 day moving average is $21.97.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, equities research analysts predict that Kenvue will post 1.05 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be issued a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 4.05%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue’s payout ratio is 154.72%.

Institutional Trading of Kenvue

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Leo Wealth LLC grew its position in shares of Kenvue by 0.3% during the 3rd quarter. Leo Wealth LLC now owns 151,611 shares of the company’s stock valued at $3,507,000 after acquiring an additional 481 shares during the period. Alerus Financial NA grew its holdings in Kenvue by 0.3% during the third quarter. Alerus Financial NA now owns 191,345 shares of the company’s stock valued at $4,426,000 after purchasing an additional 491 shares during the period. Kiley Juergens Wealth Management LLC increased its position in Kenvue by 1.9% in the fourth quarter. Kiley Juergens Wealth Management LLC now owns 27,110 shares of the company’s stock worth $579,000 after buying an additional 500 shares in the last quarter. Principle Wealth Partners LLC increased its position in Kenvue by 3.7% in the fourth quarter. Principle Wealth Partners LLC now owns 14,194 shares of the company’s stock worth $303,000 after buying an additional 500 shares in the last quarter. Finally, Wolff Wiese Magana LLC lifted its position in shares of Kenvue by 0.7% during the 3rd quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company’s stock valued at $1,781,000 after buying an additional 501 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.